An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Trial Profile

An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Hydrogen peroxide (Primary)
  • Indications Seborrhoeic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 08 Feb 2018 According to an Aclaris Therapeutics media release, data will be presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting.
    • 09 May 2017 According to an Aclaris Therapeutics media release, NDA for A-101 40% for the topical treatment of SK has been accepted by the FDA for review, based on the data from three phase III trials (see profile 257107 and 266887).The company also plans to submit a marketing authorization application (MAA) for A-101 40% for the treatment of SK in the European Union in the second half of 2017.
    • 01 Dec 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top